Skip to main content
Clinical Trials/NCT02037724
NCT02037724UnknownPhase 2

Fermented Iron-rich Supplement in Reducing Anemia

University of Ghana0 sites120 target enrollmentStarted: March 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Enrollment
120
Primary Endpoint
iron deficiency anemia

Study Overview

Brief Summary

The consequences of iron deficiency anemia in women are enormous, and especially in developing countries, as the condition adversely affects both their productive and reproductive capabilities. The study seeks to: 1) compare changes in iron status indicators among women receiving an iron-rich organic food supplement versus ferrous sulfate supplement, and 2) determine the suitable level of food supplement needed to prevent/reduce iron deficiency anemia among women in developing country settings.

A double-blind, randomized, controlled, intervention trial will be implemented in women of childbearing age, 60 women with iron deficiency anemia and 60 women with iron deficiency. After screening potential subjects (up to 500 expected), approximately 30 will be recruited into each of four study groups; assuming 30% dropout rate, to detect an increase of 30% in ferritin as significant between the two time points at 80% power and alpha value of 0.05. Subjects who meet the inclusion criteria will be randomized into the four groups consisting of: 2 control groups (daily 60mg ferrous sulfate (FS-60) or daily 10mg ferrous sulfate (FS-10)), and 2 test groups (daily 60mg iron-rich supplement (IRS-60) or 10mg iron-rich supplement (IRS-10)). Subjects will take daily FS-60 and IRS-60 under supervision for 8 weeks while subjects taking FS-10 and IRS-10 will take the supplement under supervision for 12 consecutive weeks.

Detailed Description

The design will involve screening of about 500 female adult students and staff of the University of Ghana who meet initial the inclusion criteria. Screening will involve pregnancy testing, assessment of hemoglobin, and ferritin and also administration of a health history questionnaire.

Thereafter, 120 eligible subjects will enrolled and randomized to recieve the treatment. All subjects will complete 3-day dietary record (including 2 weekdays and 1 weekend) at baseline and at endline (i.e. one week prior to treatment completion). The dietary data will be analyzed using nationally-generated food composition tables together with the ESHA food processor software. In addition, body weight and height will be measured using standard methods at baseline and end of the study. Weekly monitoring of side effects will be recorded. Fasting blood samples will be collected at baseline and endline to enable determination of anemia status and other indicators including serum ferritin, transferrin receptor and full blood count, together with C-reactive protein.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 49 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •18-49 years
  • •Regular menstruation in the last three months
  • •Hemoglobin <12 mg/dl;
  • •Serum Ferittin<20mcg/L
  • •BMI 18.5Kg/m^2 to 29.9 kg/m^2

Exclusion Criteria

  • •history of gastrointestinal or hematological disorders,
  • •taking medications that could interfere with hematopoiesis or dietary iron absorption
  • •pregnant (based on pregnancy test).

Arms & Interventions

supplement containing 60 mg iron sulfate

Other

nutrient supplement containing 60 mg of iron as ferous sulfate

Intervention: iron rich food supplement (60 mg iron) (Dietary Supplement)

supplement containing 60 mg iron sulfate

Other

nutrient supplement containing 60 mg of iron as ferous sulfate

Intervention: iron rich food supplement (10 mg iron) (Dietary Supplement)

supplement containing 60 mg iron sulfate

Other

nutrient supplement containing 60 mg of iron as ferous sulfate

Intervention: supplement containing 10 mg iron sulfate (Dietary Supplement)

iron rich food supplement (60 mg iron)

Experimental

contains 60 mg Iron

Intervention: supplement containing 60 mg iron sulfate (Dietary Supplement)

iron rich food supplement (60 mg iron)

Experimental

contains 60 mg Iron

Intervention: iron rich food supplement (10 mg iron) (Dietary Supplement)

iron rich food supplement (60 mg iron)

Experimental

contains 60 mg Iron

Intervention: supplement containing 10 mg iron sulfate (Dietary Supplement)

iron rich food supplement (10 mg iron)

Experimental

contains 10 mg of iron

Intervention: supplement containing 60 mg iron sulfate (Dietary Supplement)

iron rich food supplement (10 mg iron)

Experimental

contains 10 mg of iron

Intervention: iron rich food supplement (60 mg iron) (Dietary Supplement)

iron rich food supplement (10 mg iron)

Experimental

contains 10 mg of iron

Intervention: supplement containing 10 mg iron sulfate (Dietary Supplement)

supplement containing 10 mg iron sulfate

Other

nutrient supplement containing 10 mg of iron as ferous sulfate

Intervention: supplement containing 60 mg iron sulfate (Dietary Supplement)

supplement containing 10 mg iron sulfate

Other

nutrient supplement containing 10 mg of iron as ferous sulfate

Intervention: iron rich food supplement (60 mg iron) (Dietary Supplement)

supplement containing 10 mg iron sulfate

Other

nutrient supplement containing 10 mg of iron as ferous sulfate

Intervention: iron rich food supplement (10 mg iron) (Dietary Supplement)

Outcomes

Primary Outcomes

iron deficiency anemia

Time Frame: two and three months

Improvement of iron status with 60 mg (after two months) and 10 mg iron (after 3 months) will be assessed. The iron status measurements include, hemoglobin, ferritin, transferrin receptor and whole blood count

Secondary Outcomes

  • comparison of side effects of iron supplement(3 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Richmond Aryeetey, PhD, MPH

Senior Lecturer

University of Ghana

Similar Trials